Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2006;98:1431-1438
Published online before print April 27, 2006, doi: 10.1161/01.RES.0000224114.65109.4e
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
98/11/1431    most recent
01.RES.0000224114.65109.4ev1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hinton, R. B.
Right arrow Articles by Yutzey, K. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hinton, R. B., Jr
Right arrow Articles by Yutzey, K. E.
Related Collections
Right arrow Valvular heart disease
Right arrow Pediatric and congenital heart disease, including cardiovascular surgery
Right arrow Cardiac development
(Circulation Research. 2006;98:1431.)
© 2006 American Heart Association, Inc.


Integrative Physiology

Extracellular Matrix Remodeling and Organization in Developing and Diseased Aortic Valves

Robert B. Hinton, Jr*, Joy Lincoln*, Gail H. Deutsch, Hanna Osinska, Peter B. Manning, D. Woodrow Benson, Katherine E. Yutzey

From the Divisions of Cardiology (R.B.H., D.W.B.), Molecular Cardiovascular Biology (J.L., H.O., K.E.Y.), Pathology (G.H.D.), and Cardiothoracic Surgery (P.B.M.), Cincinnati Children’s Hospital Medical Center, Ohio.

Correspondence to Katherine E. Yutzey, PhD, Associate Professor of Pediatrics, Division of Molecular Cardiovascular Biology, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Ave, ML 7020, Cincinnati, OH 45229-3039. Katherine.Yutzey{at}cchmc.org


*    Abstract
up arrowTop
*Abstract
down arrowIntroduction
down arrowMaterials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Heart valve disease is an important cause of morbidity and mortality worldwide. Little is known about valve disease pathogenesis, but increasing evidence implicates a genetic basis for valve disease, suggesting a developmental origin. Although the cellular and molecular processes involved in early valvulogenesis have been well described, less is known about the regulation of valve extracellular matrix (ECM) organization and valvular interstitial cell (VIC) distribution that characterize the mature valve structure. Histochemistry, immunohistochemistry, and electron microscopy were used to examine ECM organization, VIC distribution, and cell proliferation during late valvulogenesis in chicken and mouse. In mature valves, ECM organization is conserved across species, and developmental studies demonstrate that ECM stratification begins during late embryonic cusp remodeling and continues into postnatal life. Cell proliferation decreases concomitant with ECM stratification and VIC compartmentalization. Explanted, stenotic bicuspid aortic valves (BAVs) from pediatric patients were also examined. The diseased valves exhibited disruption of the highly organized ECM and VIC distribution seen in normal valves. Cusps from diseased valves were thickened with increased and disorganized collagens and proteoglycans, decreased and fragmented elastic fibers, and cellular disarray without calcification or cell proliferation. Taken together, these studies show that normal valve development is characterized by spatiotemporal coordination of ECM organization and VIC compartmentalization and that these developmental processes are disrupted in pediatric patients with diseased BAVs.


Key Words: valve disease • extracellular matrix • valvular interstitial cells • cardiac development


*    Introduction
up arrowTop
up arrowAbstract
*Introduction
down arrowMaterials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Valve replacement, usually for aortic valve disease, is the second most common cardiac operation performed in the US, and the need for reintervention is common.1,2 Little is known about valve disease pathogenesis, but increasing evidence implicates a genetic basis for valve malformation, suggesting a developmental origin.3–7 Valve development is initiated with endothelial-mesenchymal transformation of the endocardium in the outflow tract and atrioventricular (AV) canal to form endocardial cushions, and this process has been extensively studied.8,9 Endocardial cushions subsequently elongate as a result of cell proliferation and undergo expansion and remodeling of the extracellular matrix (ECM) to form the mature semilunar valve cusps and AV valve leaflets. The morphogenetic events that characterize valvulogenesis during late embryonic and postnatal development are largely unknown.10

The mature valve structure is composed of ECM, valvular interstitial cells (VICs), and overlying endothelial cells. The ECM is composed of 3 highly organized overlapping layers with distinct mechanical properties arranged in orientation to blood flow in the semilunar and AV valves.11,12 The primary components of these layers are collagens, proteoglycans, and elastin. In aortic valves, the fibrosa, or arterial aspect of the cusp, is composed primarily of collagen fibers; the spongiosa, or central aspect, consists predominantly of loosely arranged proteoglycans; and the ventricularis, or ventricular aspect, contains elastin fibers.13–15 Studies of diseased valves in adult patients have shown cusp and leaflet thickening, collagen fiber disorganization, increased VIC density, and calcification.16,17 However, the interpretation of these histopathological studies has been limited by common valve disease comorbidities such as aging, hypertension, and hypercholesterolemia.

In this study, we examined the processes of ECM stratification and VIC distribution during valve development in chicken and mouse. These findings were applied to histopathological assessment of explanted, stenotic bicuspid aortic valves (BAV) from pediatric patients. We found that late valvulogenesis is characterized by spatiotemporal coordination of ECM organization and VIC compartmentalization, and the developmental programs underlying cusp remodeling contribute to ongoing valve growth and maintenance in postnatal life. These developmental processes are disrupted in pediatric patients with a diseased aortic valve resulting from a viable, congenital malformation (BAV).


*    Materials and Methods
up arrowTop
up arrowAbstract
up arrowIntroduction
*Materials and Methods
down arrowResults
down arrowDiscussion
down arrowReferences
 
Chicken and Mouse Embryo Collection
White leghorn chicken eggs (Spafas Inc, Roanoke Ill) were incubated at 38°C in high humidity, and hearts were collected at Hamburger–Hamilton stages 29, 36, and 42, corresponding to embryonic day 6 (E6), E10, and E16, respectively.18 Juvenile chicken hearts (Tewes Poultry Farm, Erlanger, Ky) were collected at 8 weeks. Mouse embryos were obtained from timed pregnancies with observation of a copulation plug designated as E0.5. Mouse hearts were collected at E12.5, E14.5, E18.5, 2 weeks, and 4 months. Valve tissue was also obtained from rabbit (3 months) and sheep (20 months). All animal procedures were performed in accordance with institutional guidelines.

Pediatric Aortic Valve Tissue Collection
Human specimens were obtained from pediatric patients with aortic valve disease undergoing aortic valve replacement (affected) and at the time of autopsy from age-matched pediatric patients who died of noncardiac causes (control). Medical records were reviewed, and patients with a history of a genetic syndrome, infective endocarditis, or rheumatic heart disease were excluded. These studies were approved by the Institutional Review Board at Cincinnati Children’s Hospital Medical Center.

Histochemistry
Hearts or valve tissue were dissected, fixed, and processed as previously described.19 Movat’s modified pentachrome stain was used to examine ECM organization and VIC distribution on 6- to 8-µm sections of developing, mature, and diseased valves.20 Von Kossa staining was used to evaluate the presence of calcification in control and diseased valves.20 Images were obtained using an Olympus BX60 microscope and captured using Advanced SPOT image software.

Immunohistochemistry
Mouse monoclonal antibodies directed against aggrecan (Chemicon; 1:200), collagen type 3 (Iowa 3B2; 1:200), elastin (Sigma; 1:1000), and tenascin (Iowa M1-B4; 1:200) were used to evaluate ECM organization as previously described.19 The tenascin and collagen type 3 antisera were purchased from the Developmental Studies Hybridoma Bank developed with the National Institute of Child Health and Human Development and maintained by the University of Iowa. Antigen retrieval was used for the elastin antibody using antigen unmasking solution (Vector Laboratories). Pretreatment was used for the aggrecan and collagen type 3 antibodies, as previously described with modification.19 A universal streptavidin/biotin and diaminobenzidine detection system (Pierce) was used for colorimetric detection.

Electron Microscopy
Transmission electron microscopy (Hitachi 7600) of mouse valve tissue was performed as previously described.21 For visualization of collagens and elastins, sections were stained with 5% tannic acid aqueous solution, followed by 1% uranyl acetate, and counterstained with lead citrate.22

Analysis of Cell Proliferation, Distribution, and Morphology
Cell proliferation was assessed on 8-µm mouse sections using the rabbit polyclonal antibody anti–phospho-Histone H3 (P-Histone H3, 1:100; Upstate). The proliferation index (proliferating cells per total cells) was calculated at serial time points (E12.5, E14.5, E18.5, 2 weeks, 4 months). In chicken, cell number, cusp thickness, and cusp area were measured in sectioned valve structures. Cell density (cell number per area) was calculated in whole valve structures (E6, E10, E16, and 8 weeks) and in individual cusp layers (cE16, 8 weeks) using ImageJ software (NIH). Cusp thickness in developing, mature, and diseased valves was measured in the proximal half of the valve. For each data point, measurements were made in triplicate from 3 independent samples.

Statistical Analysis
Student t test or 1-way ANOVA was used to compare groups. Findings are reported as mean with SEM. A probability value of <0.05 was considered significant.


*    Results
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
*Results
down arrowDiscussion
down arrowReferences
 
ECM Organization of the Mature Aortic Valve Is Conserved Across Species
Organization of the mature aortic valve in animals with 4 chambered hearts commonly used in cardiovascular research was examined histologically (Figure 1). Aortic valve cusps from human, sheep, chicken, rabbit, and mouse demonstrated similar ECM protein composition and stratification, as well as qualitatively increased cell density in the ventricularis or ventricular aspect of the cusp. In all species, there was collagen (yellow) in the fibrosa or arterial aspect of the cusp, elastic fibers (black) in the ventricularis, and proteoglycans (blue) in the spongiosa, as indicated by Movat’s pentachrome stain. Elastic fibers were concentrated at the proximal portion of the cusp and extended to the leading or closing edge (arrowheads, Figure 1A, 1C, 1E, 1G, and 1I). Although the overall pattern of ECM organization in the mature valve was conserved, differences were observed among species. For example, larger mammals (human and sheep) have more abundant collagen and elastin in the fibrosa and ventricularis, respectively, and more discretely defined ECM organization compared with chicken, rabbit, and mouse (Figure 1A through 1F). Further, the chicken has a disproportionately thicker cusp with a well-defined ECM, similar to human and sheep, but relatively increased proteoglycan compared with collagen and elastin. In contrast, the rabbit and mouse have less distinct ECM layering and qualitatively increased VIC density throughout the valve cusp (Figure 1G through 1J). In rabbit, there is overlap of the fibrosa and spongiosa layers of the cusp, as evidenced by the teal appearance caused by blue and yellow staining (Figure 1G and 1H). The mature aortic valve structure in mouse has relatively less collagen in the fibrosa and less elastin in the ventricularis compared with larger animals (Figure 1I and 1J). These differences in ECM organization may be attributable, in part, to variation in size and hemodynamic burden of the different species; however, overall ECM protein composition and basic trilaminar organization in the mature valve structure is conserved.


Figure 1
View larger version (51K):
[in this window]
[in a new window]
 
Figure 1. ECM organization and VIC compartmentalization in the mature semilunar valve cusps. Human (A and B), sheep (C and D), chicken (E and F), rabbit (G and H), and mouse (I and J) aortic valves were examined using Movat’s pentachrome stain. Boxes represent areas of high magnification shown in B, D, F, H, and J. All species demonstrated collagen in the fibrosa (F) and annulus (asterisks), elastin in the ventricularis (V) extending to the leading edge only (arrowheads), and diffuse proteoglycan predominantly in the spongiosa (S). Movat’s pentachrome stain identifies elastin fibers as black, collagens as yellow, proteoglycans as blue, muscle as red, and cell nuclei as purple. Close proximity of collagen and proteoglycan appears teal. Note species size differences, with scale bar=150 µm in A, C, E, G, and I; and scale bar=50 µm in B, D, F, H, and J.

Valve Remodeling Is Characterized by Stratified ECM and Decreased Cell Density
To determine the timing of ECM organization in the developing chicken (c) and mouse (m) semilunar and AV valves, serial time points corresponding to 3 major morphogenetic processes during valvulogenesis, namely endocardial cushion formation, cushion elongation, and cusp and leaflet remodeling, were examined using Movat’s pentachrome stain. Similar results were observed in semilunar and AV valves in both chicken and mouse (Figure 2). During cushion formation (cE6, mE12.5) and cushion elongation (cE10, mE15.5), proteoglycan is diffusely expressed throughout developing valves, and ECM stratification is not observed. Distinct layers (fibrosa and spongiosa), reminiscent of the mature valve structure, were first appreciated during cusp and leaflet remodeling (cE16, mE18.5), marking the beginning of ECM stratification (arrows, Figure 2C, 2F, 2I, and 2L). During cusp and leaflet remodeling, collagen is expressed in the fibrosa of both semilunar (arterial aspect) and AV (ventricular aspect) valves. Proteoglycan is the primary component of the spongiosa in both semilunar and AV valves. Elastin is present in the aorta at all time points but appears relatively late in the ventricularis. ECM stratification is a central feature of chicken and mouse valvulogenesis and begins during late embryonic cusp and leaflet remodeling; however, the mature valve structure is not appreciated until postnatal life (compare with Figure 1).


Figure 2
View larger version (124K):
[in this window]
[in a new window]
 
Figure 2. ECM organization and VIC compartmentalization in the developing chicken and mouse heart valves. Chicken (A through C and G through I) and mouse (D through F and J through L) semilunar (A through F) and atrioventricular (G through L) valves were examined using Movat’s pentachrome stain during endocardial cushion formation (cE6, mE12.5) (A, D, G, and J), cushion elongation (cE10, mE14.5) (B, E, H, and K), and cusp remodeling (cE16, mE18.5) (C, F, I, and L). In chicken and mouse, ECM stratification and differential VIC distribution in semilunar valve cusps and AV valve leaflets are first appreciated during cusp and leaflet remodeling (arrows) (C, F, I, and L). *Aorta (A through F).

To investigate VIC distribution relative to valve morphogenesis in the embryonic (E6, E10, and E16) and juvenile (8 weeks) chicken aortic valve, cell number, cusp thickness, and cusp area were quantified (Table). Cusp area increased approximately 50-fold from the endocardial cushion stage to the postnatal juvenile stage (0.065 versus 3.4 mm2), corresponding with a 7-fold decrease in cell density (11 289 versus 1589 cells/mm2). In the early stages of valve development (cushion formation, cushion elongation), there was uniform cell density in the valve primordia. During later stages (cusp remodeling, juvenile), variation in cell distribution was observed in the emerging stratified ECM layers, as evidenced by different cell densities in the layers. During both cusp remodeling and postnatal juvenile stages of development, cell density was significantly higher in the fibrosa and ventricularis layers of the aortic valve cusps when compared with the spongiosa (Table). Importantly, the findings demonstrating VIC compartmentalization in juvenile chicken correlate with previous reports in juvenile human valves.23 In contrast to VIC density, endothelial cell density was constant from the cushion stage to the juvenile stage. These findings demonstrate that VIC compartmentalization follows a similar time course as ECM stratification during cusp remodeling.


View this table:
[in this window]
[in a new window]
 
Table 1. Differential Distribution of VICs in Developing and Juvenile Chicken Aortic Valves

Aortic Valve ECM Stratification Begins During Cusp Remodeling and Continues Into Postnatal Life
Expression patterns of specific ECM proteins were examined during cushion elongation (E10), cusp remodeling (E16), and the juvenile cusp (8 weeks) in chicken to assess ECM organization (Figure 3). Aggrecan, a chondroitin sulfate proteoglycan and a constituent of cartilage, is expressed during cushion elongation and is present in the fibrosa and spongiosa during the cusp remodeling and juvenile stages (Figure 3A through 3C). Aggrecan is strongly expressed in the annulus during cusp remodeling but is absent from the annulus during the juvenile stage. Collagen type 3, an abundant collagen in valve tissue and cartilage, is present in the fibrosa with aggrecan during cushion elongation, cusp remodeling, and juvenile stages (Figure 3D through 3F). Elastin, a vascular matrix protein, is present in the proximal ventricularis during cusp remodeling and expression increases during the juvenile stage (Figure 3G through 3I). Tenascin, a large structural matrix protein also expressed in tendon, is localized to the annulus during cushion elongation, and extends into the fibrosa and the ventricular endothelium during cusp remodeling (Figure 3J through 3L). Interestingly, aggrecan and tenascin (markers of cartilage and tendon respectively) are expressed in the fibrosa. Both collagen type 3 and elastin are expressed in the aorta throughout embryonic development, but only collagen type 3 is present in the annulus. These studies demonstrate that specific ECM proteins organize into stratified layers during cusp remodeling. This ECM remodeling continues into postnatal life, suggesting that mechanisms of prenatal valve development may also be active in postnatal valve growth and maintenance.9,10


Figure 3
View larger version (100K):
[in this window]
[in a new window]
 
Figure 3. ECM protein expression and organization during chicken valve maturation. Expression of aggrecan (A through C), collagen type 3 (D through F), elastin (G through I), and tenascin (J through L) was examined during the cushion elongation (E10), cusp remodeling (E16), and juvenile (8 weeks) stages. ECM organization into stratified layers is first appreciated during cusp remodeling and continues into postnatal life. Aggrecan is diffusely expressed throughout the cusp, with increased expression in the fibrosa (arrows) (B and C); collagen type 3 is expressed in the fibrosa, annulus, and aorta (arrows) (E and F); elastin is expressed in the proximal ventricularis and aorta (arrows) (H and I); and tenascin is expressed in the fibrosa, annulus, and ventricular endothelial layer (arrows) (K and L).

Reduction in Cell Proliferation Is a Feature of Valve Remodeling
To investigate cell proliferation, developing and mature semilunar and AV valves in mice were examined during cushion formation (E12.5), cusp remodeling (E18.5), juvenile (2 weeks), and adult (4 months) stages using the mitotic cell marker P-Histone H324(Figure 4). In the semilunar valves, the cell proliferation index decreased from 30% in the outflow tract endocardial cushions (Figure 4A) to 5% during cusp remodeling (Figure 4B) and 1% during the juvenile stage. In the AV valves, the cell proliferation index decreased from 36% in the AV endocardial cushions (Figure 4C) to 6% during leaflet remodeling (Figure 4D) and 2% during the juvenile stage. Cell proliferation, as indicated by Histone H3 phosphorylation, was not detected in adult semilunar cusps or AV leaflets (Figure 4E). As previously reported, myocardial cell proliferation was evident at all embryonic time points examined (data not shown).25 These findings demonstrate that cell proliferation in developing valves is dramatically reduced during the cusp remodeling and juvenile stages, suggesting that the increased valve size noted during these stages is attributable, in large part, to increased ECM production but not cell hyperplasia.


Figure 4
View larger version (40K):
[in this window]
[in a new window]
 
Figure 4. Interstitial cell proliferation decreases during mouse semilunar and AV valve development. Cell proliferation in semilunar (A and B) and AV (C and D) valves was examined using P-Histone H3 during endocardial cushion formation (E12.5) (A and C), cusp and leaflet remodeling (E18.5) (B and D), juvenile (2 weeks), and adult (4 months) stages. The proliferation index decreases significantly during late embryonic development and early postnatal life and was not detected in the adult (E) (ANOVA P<0.0001). No difference was detected between semilunar and AV valves at the stages examined.

Ultrastructural Analysis of the Mouse Aortic Valve Demonstrates That ECM Organization Begins During Cusp Remodeling and Continues After Birth
Transmission electron microscopy was used to assess ECM organization in developing and mature aortic valves in mouse (Figure 5). During cushion elongation (E14.5; Figure 5A and 5B), unassembled collagens, proteoglycans, and elastin precursors are distributed throughout the primordial valve structure (Figure 5B). During cusp remodeling (E18.5), rudimentary collagen and elastin fiber fragments are in close proximity to proteoglycans. Short collagen fibers are present predominantly in the fibrosa, whereas elastin fiber fragments are present in the ventricularis (data not shown). During the juvenile stage (2 weeks; Figure 5C and 5F), extensive networks of collagen fibers are present in the fibrosa (Figure 5C and 5E), and organized elastin fibers are present in the ventricularis (Figure 5C and 5F). Whereas elastin precursors and fiber fragments are still observed at the juvenile stage, the majority of elastin fibers are highly organized, consistent with ongoing remodeling during postnatal life. These findings in mouse aortic valves demonstrate that ECM stratification begins during late embryonic development, and the ECM becomes more highly organized during postnatal life.


Figure 5
View larger version (146K):
[in this window]
[in a new window]
 
Figure 5. Ultrastructural analysis of ECM organization in developing and mature mouse aortic valves. During cushion elongation (A and B) (mE14.5), mesenchymal cells (A) are present in unorganized ECM (B). Arrow indicates collagens; arrowhead, elastins; and curved arrow, proteoglycans. During the postnatal juvenile stage (C through F) (2 weeks), the ECM is highly organized and the mature valve structure is demonstrated (C). A synthetic VIC from the base of the cusp is demonstrated (D). Arrows indicate abundant mitochondria and rough endoplasmic reticulum; #, synthetic vesicles; and *, newly synthesized ECM. In the fibrosa, highly organized collagen fibers are evident (arrows) (E); in the ventricularis, mature elastic fibers are shown (arrowheads) (F). The fibrosa is oriented toward the top of C, E, and F. The scale bar (upper right corner each panel) is 50 µm in A; 2 µm in C; 250 nm in B, E, and F; and 500 nm in D.

VIC distribution and morphology were also evaluated in the developing aortic valves of mouse (Figure 5). VICs were distinguished from endothelial cells by position and the lack of gap junctions. During cushion elongation, VICs were mesenchymal in appearance and loosely associated with ECM. However, during the juvenile stage, VICs become differentially distributed in ECM layers. In the fibrosa and ventricularis, VICs are embedded in collagens and elastins, but in the spongiosa, mesenchymal VICs are loosely associated with proteoglycans. VICs with a synthetic phenotype, as indicated by abundant mitochondria, rough endoplasmic reticulum, hyperactivated nuclei, and exocytosis of synthetic vesicles, were present in the cusp remodeling and juvenile stages26(Figure 5D). These findings demonstrate VIC compartmentalization corresponds temporally with ECM synthesis and stratification.

ECM Organization and VIC Compartmentalization Are Disrupted in Pediatric Aortic Valve Disease
ECM organization and VIC compartmentalization were examined in pediatric aortic valve disease, in which primary effects on these processes can be determined without the confounding factors of aging, hypertension, and hypercholesterolemia present in adults with valve disease. Explanted valve tissue was obtained from pediatric patients with BAV undergoing aortic valve replacement (median age 11 months [range, 1 to 184], n=6) and compared with age-matched controls (median age 6 months [range, 1 to 168], n=6). In each case, aortic stenosis was the indication for surgery. Three cases had previous balloon angioplasty, and 1 case had prior surgical valvotomy. Histopathology with Movat’s pentachrome stain demonstrated that ECM organization was similarly disrupted in all explanted diseased valves when compared with controls (Figure 6). Specifically, ECM trilaminar stratification was lost, as evidenced by the presence of disorganized collagens and proteoglycans in all layers (Figure 6B and 6C). Elastin fiber content appeared reduced, but collagen and proteoglycan content were increased substantially, as evidenced by the significant increase in cusp thickness (diseased valves=1.68±0.14 mm, control valves=0.32±0.04 mm, P<0.0001; Figure 6D). In addition, collagen and elastin fibers are disorganized, as evidenced by abnormal fiber orientation and fragmentation. VIC compartmentalization was also disrupted, as evidenced by cellular disarray in the form of cell clusters and large relatively cell-free areas in all aspects of the interstitium. However, there was no increase in cell proliferation, as determined by P-Histone H3 immunohistochemistry, and there was no evidence of calcification by von Kossa staining (data not shown). These findings demonstrate that pediatric aortic valve disease with underlying BAV is characterized by excessive ECM production, ECM disorganization, and VIC disarray.


Figure 6
View larger version (40K):
[in this window]
[in a new window]
 
Figure 6. Diseased pediatric bicuspid aortic valves demonstrate increased ECM production, ECM disorganization, and VIC disarray. Representative cross-sections from control (A) and diseased (B) aortic valve cusps with higher magnification of boxed area (C). Normal cusps have highly organized stratified ECM (bidirectional arrows) (A), and diseased cusps have increased and disorganized collagens and proteoglycans, decreased and fragmented elastic fibers, and clusters of VICs with loss of compartmentalization (arrowheads) (C). Quantitative analysis of aortic valve cusp thickness (D) demonstrates significantly increased cusp thickness in diseased valves, which can be attributed to increased ECM production (P<0.0001). The fibrosa is oriented upward. Scale bar=100 µm.


*    Discussion
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowResults
*Discussion
down arrowReferences
 
ECM organization and VIC compartmentalization, hallmarks of the mature valve structure, begin during late embryonic cusp remodeling and continue into postnatal life (Figure 7). The substantial cell proliferation appreciated during early valve development is markedly reduced during cusp remodeling, suggesting that late embryonic and postnatal valve growth is a function of increased ECM production. The coordination of ECM organization and VIC compartmentalization during valvulogenesis suggests that developmental mechanisms regulate both processes. In diseased aortic valves from pediatric patients with BAV, excessive ECM production, ECM disorganization, and VIC disarray without calcification are observed (Figure 7D). The pathogenesis of aortic valve disease in pediatric patients with BAV may be the result of dysregulation of the molecular hierarchies that control late valve development, ultimately leading to increased cusp thickness and ECM disorganization.


Figure 7
View larger version (27K):
[in this window]
[in a new window]
 
Figure 7. Model of semilunar valve development and disease. During early embryonic valve development, endocardial cushion formation (A), and cushion elongation (B) occur, and during late embryonic valve development, cusp remodeling (C) results in stratified layers of ECM and differential distribution of VICs. Cell density decreases dramatically during valvulogenesis. ECM organization and VIC compartmentalization begin during remodeling, and the highly organized mature valve structure is realized in postnatal life. Pediatric aortic valve disease (D) is characterized by ECM disorganization and VIC disarray. Red corresponds with myocardium, blue with proteoglycans, yellow with collagens, and gray with elastin.

ECM Organization and VIC Compartmentalization Begin During Late Embryonic Remodeling and Continue Into Postnatal Life
The highly organized trilaminar stratification of ECM proteins in aortic valves was conserved across mammalian and avian species. During late embryonic cusp remodeling, we observed that cell proliferation decreased and ECM organization and VIC compartmentalization were spatially and temporally coordinated. Similar findings were recently demonstrated in fetal and postnatal human valves.27 Considerable valve growth occurs during postnatal life after formation of the organized trilaminar ECM stratification that characterizes the mature valve structure. The marked increase in cusp area compared with cell number indicates that the major increase in valve size is caused by increased ECM protein synthesis that far outpaces cell proliferation. ECM stratification is initiated with the diversification of VICs that express specific matrix proteins and are less proliferative.15,28 The differential distribution of VICs in the mature valve structure may reflect functional diversity within these cell populations.

ECM Protein Gene Mutations Cause Human Valve Disease
Mutations in several ECM genes result in valve disease in humans and clearly indicate the importance of strict ECM regulation for normal valve function. For example, mutations in the fibrillin 1 gene cause BAV and mitral valve prolapse, whereas mutations in the elastin gene cause disease of the aortic, mitral, and pulmonary valves.29–31 In addition, mitral valve prolapse and pulmonary valve stenosis have been linked to mutations in the collagen type 3 and tenascin X genes.32,33 Therefore, a structural or functional defect in a single ECM protein is sufficient to cause valve disease, but the mechanisms by which ECM protein insufficiency or dysfunction lead to valve pathogenesis is not known. The disorganization of ECM structure in congenitally malformed valves may lead to abnormal signaling cascades, which in turn result in VIC dysregulation of ECM synthesis, consistent with the idea that valve disease has developmental origins.26,34–37

Increased ECM Production, ECM Disorganization, and VIC Disarray Are Cardinal Features of the Stenotic BAV in Pediatric Patients
In every age group, but particularly in the pediatric patient, BAV underlies the majority of cases of aortic valve disease.5,38 BAV is the most common congenital cardiovascular malformation, with an incidence of approximately 1% in the general population.39 Recent studies have found that BAV is heritable, or caused by major genetic effects.4 A benefit of studying aortic valve disease in the pediatric patient is that it avoids confounding valve disease comorbidities, such as aging, hypertension, and hypercholesterolemia, that complicate the interpretation of histopathological studies of aortic valve disease in adult patients. A major finding of this study is that stenotic BAVs in pediatric patients exhibit increased ECM production, ECM disorganization, and VIC disarray without calcification, providing further support for the idea that faulty developmental programs result in abnormal and increased ECM and consequently valve disease. Taken together, these findings suggest that aortic valve disease has its origins in valve development.

Normal valve development is characterized by the spatiotemporal coordination of ECM organization and VIC compartmentalization. Signaling pathways involved in valvulogenesis are increasingly becoming known; however, the molecular regulation of normal valve development and the role of these pathways in valve disease are unclear.10 In diseased aortic valves from pediatric patients with BAV, these developmental processes are disrupted, resulting in cusp thickening, ECM disorganization, and VIC disarray without calcification. Further studies are required to determine the extent to which these features can be extrapolated to other types of valve disease. However, based on the findings reported here, we speculate that a viable congenital malformation (BAV) can lead to progressive dysregulation of ECM organization and VIC compartmentalization characteristic of valve disease.


*    Acknowledgments
 
This work was supported by grants from the American Heart Association (0425366B to J.L.) and the NIH (HD43005 to R.B.H., HL069712 to D.W.B., and HL074728 to D.W.B. and K.E.Y.). We thank Dr David Witte for coordinating collection of autopsy specimens; Drs Jeanne James and Pirooz Eghtesady for providing aortic valve tissue from rabbit and sheep, respectively; Amy Poland, Raisa Klevitsky, and Scott Baker for technical assistance; and Andreas Lange for art work.


*    Footnotes
 
*Both authors contributed equally to this study. Back

Original received March 6, 2006; revision received April 7, 2006; accepted April 18, 2006.


*    References
up arrowTop
up arrowAbstract
up arrowIntroduction
up arrowMaterials and Methods
up arrowResults
up arrowDiscussion
*References
 

  1. Thom T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O’Donnell C, Kittner S, Lloyd-Jones D, Goff DC Jr, Hong Y, Adams R, Friday G, Furie K, Gorelick P, Kissela B, Marler J, Meigs J, Roger V, Sidney S, Sorlie P, Steinberger J, Wasserthiel-Smoller S, Wilson M, Wolf P; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics–2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2006; 113: e85–e151.[Free Full Text]
  2. Keane JF, Driscoll DJ, Gersony WM, Hayes CJ, Kidd L, O’Fallon WM, Pieroni DR, Wolfe RR, Weidman WH. Second natural history study of congenital heart defects. Results of treatment of patients with aortic valvar stenosis. Circulation. 1993; 87 (suppl I): I-16–I-27.[Medline] [Order article via Infotrieve]
  3. Huntington K, Hunter AG, Chan KL. A prospective study to assess the frequency of familial clustering of congenital bicuspid aortic valve. J Am Coll Cardiol. 1997; 30: 1809–1812.[Abstract]
  4. Cripe L, Andelfinger G, Martin LJ, Shooner K, Benson DW. Bicuspid aortic valve is heritable. J Am Coll Cardiol. 2004; 44: 138–143.[Abstract/Free Full Text]
  5. Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. Circulation. 2005; 111: 920–925.[Abstract/Free Full Text]
  6. Nesta F, Leyne M, Yosefy C, Simpson C, Dai D, Marshall JE, Hung J, Slaugenhaupt SA, Levine RA. New locus for autosomal dominant mitral valve prolapse on chromosome 13: clinical insights from genetic studies. Circulation. 2005; 112: 2022–2030.[Abstract/Free Full Text]
  7. Garg V, Muth AN, Ransom JF, Schluterman MK, Barnes R, King IN, Grossfeld PD, Srivastava D. Mutations in NOTCH1 cause aortic valve disease. Nature. 2005; 437: 270–274.[CrossRef][Medline] [Order article via Infotrieve]
  8. Eisenberg LM, Markwald RR. Molecular regulation of atrioventricular valvuloseptal morphogenesis. Circ Res. 1995; 77: 1–6.[Free Full Text]
  9. Person AD, Klewer SE, Runyan RB. Cell biology of cardiac cushion development. Int Rev Cytol. 2005; 243: 287–335.[CrossRef][Medline] [Order article via Infotrieve]
  10. Armstrong EJ, Bischoff J. Heart valve development: endothelial cell signaling and differentiation. Circ Res. 2004; 95: 459–470.[Abstract/Free Full Text]
  11. Gross L, Kugel M. Topographic anatomy and histology of the valves in the human heart. Am J Pathol. 1931; 7: 445–473.
  12. Schoen FJ. Cardiac valves and valvular pathology: update on function, disease, repair, and replacement. Cardiovasc Pathol. 2005; 14: 189–194.[CrossRef][Medline] [Order article via Infotrieve]
  13. Schoen FJ. Aortic valve structure-function correlations: role of elastic fibers no longer a stretch of the imagination. J Heart Valve Dis. 1997; 6: 1–6.[Medline] [Order article via Infotrieve]
  14. Vesely I. The role of elastin in aortic valve mechanics. J Biomech. 1998; 31: 115–123.[Medline] [Order article via Infotrieve]
  15. de Lange FJ, Moorman AF, Anderson RH, Manner J, Soufan AT, de Gier-de Vries C, Schneider MD, Webb S, van den Hoff MJ, Christoffels VM. Lineage and morphogenetic analysis of the cardiac valves. Circ Res. 2004; 95: 645–654.[Abstract/Free Full Text]
  16. Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O’Brien KD. Characterization of the early lesion of "degenerative" valvular aortic stenosis. Histological and immunohistochemical studies. Circulation. 1994; 90: 844–853.[Abstract/Free Full Text]
  17. Rabkin E, Aikawa M, Stone JR, Fukumoto Y, Libby P, Schoen FJ. Activated interstitial myofibroblasts express catabolic enzymes and mediate matrix remodeling in myxomatous heart valves. Circulation. 2001; 104: 2525–2532.[Abstract/Free Full Text]
  18. Hamburger V, Hamilton H. Stages of chick development after the initial appearance of the primitive streak. J Morphol. 1951; 88: 49–92.[CrossRef]
  19. Lincoln J, Alfieri CM, Yutzey KE. Development of heart valve leaflets and supporting apparatus in chicken and mouse embryos. Dev Dyn. 2004; 230: 239–250.[CrossRef][Medline] [Order article via Infotrieve]
  20. Sheehan D, Hrapchak B. Theory and Practice of Histotechnology. 2nd ed. Columbus, Ohio: Lipshaw; 1987.
  21. Fewell JG, Osinska H, Klevitsky R, Ng W, Sfyris G, Bahrehmand F, Robbins J. A treadmill exercise regimen for identifying cardiovascular phenotypes in transgenic mice. Am J Physiol. 1997; 273: H1595–H1605.[Medline] [Order article via Infotrieve]
  22. Hayat M. Principles and Techniques of Electron Microscopy. Cambridge, UK: Cambridge University Press; 2000.
  23. Rabkin-Aikawa E, Mayer JE Jr, Schoen FJ. Heart valve regeneration. Adv Biochem Eng Biotechnol. 2005; 94: 141–179.[Medline] [Order article via Infotrieve]
  24. Wei L, Imanaka-Yoshida K, Wang L, Zhan S, Schneider MD, DeMayo FJ, Schwartz RJ. Inhibition of Rho family GTPases by Rho GDP dissociation inhibitor disrupts cardiac morphogenesis and inhibits cardiomyocyte proliferation. Development. 2002; 129: 1705–1714.[Abstract/Free Full Text]
  25. Akiyama H, Chaboissier MC, Behringer RR, Rowitch DH, Schedl A, Epstein JA, de Crombrugghe B. Essential role of Sox9 in the pathway that controls formation of cardiac valves and septa. Proc Natl Acad Sci U S A. 2004; 101: 6502–6507.[Abstract/Free Full Text]
  26. Rabkin-Aikawa E, Farber M, Aikawa M, Schoen FJ. Dynamic and reversible changes of interstitial cell phenotype during remodeling of cardiac valves. J Heart Valve Dis. 2004; 13: 841–847.[Medline] [Order article via Infotrieve]
  27. Aikawa E, Whittaker P, Farber M, Mendelson K, Padera RF, Aikawa M, Schoen FJ. Human semilunar cardiac valve remodeling by activated cells from fetus to adult: implications for postnatal adaptation, pathology, and tissue engineering. Circulation. 2006; 113: 1344–1352.[Abstract/Free Full Text]
  28. Abdelwahid E, Pelliniemi LJ, Jokinen E. Cell death and differentiation in the development of the endocardial cushion of the embryonic heart. Microsc Res Tech. 2002; 58: 395–403.[CrossRef][Medline] [Order article via Infotrieve]
  29. Eronen M, Peippo M, Hiippala A, Raatikka M, Arvio M, Johansson R, Kahkonen M. Cardiovascular manifestations in 75 patients with Williams syndrome. J Med Genet. 2002; 39: 554–558.[Abstract/Free Full Text]
  30. Hinton R, Deutsch G, Pearl J, Hobart H, Morris C, Benson D. Bilateral semilunar valve disease in a child with partial deletion of the Williams-Beuren syndrome region is associated with elastin haploinsufficiency. J Heart Valve Dis. In press.
  31. Milewicz DM, Dietz HC, Miller DC. Treatment of aortic disease in patients with Marfan syndrome. Circulation. 2005; 111: e150–e157.[Free Full Text]
  32. Jaffe AS, Geltman EM, Rodey GE, Uitto J. Mitral valve prolapse: a consistent manifestation of type IV Ehlers-Danlos syndrome. The pathogenetic role of the abnormal production of type III collagen. Circulation. 1981; 64: 121–125.[Abstract/Free Full Text]
  33. Tsai-Goodman B, Martin RP, Pope FM, Stuart AG. Pulmonary valvuloplasty in a case of vascular Ehlers-Danlos syndrome. Catheter Cardiovasc Interv. 2002; 57: 92–94.[CrossRef][Medline] [Order article via Infotrieve]
  34. Dietz HC, Mecham RP. Mouse models of genetic diseases resulting from mutations in elastic fiber proteins. Matrix Biol. 2000; 19: 481–488.[CrossRef][Medline] [Order article via Infotrieve]
  35. Brooke BS, Karnik SK, Li DY. Extracellular matrix in vascular morphogenesis and disease: structure versus signal. Trends Cell Biol. 2003; 13: 51–56.[CrossRef][Medline] [Order article via Infotrieve]
  36. Durbin AD, Gotlieb AI. Advances towards understanding heart valve response to injury. Cardiovasc Pathol. 2002; 11: 69–77.[CrossRef][Medline] [Order article via Infotrieve]
  37. Walker GA, Masters KS, Shah DN, Anseth KS, Leinwand LA. Valvular myofibroblast activation by transforming growth factor-beta: implications for pathological extracellular matrix remodeling in heart valve disease. Circ Res. 2004; 95: 253–260.[Abstract/Free Full Text]
  38. Ward C. Clinical significance of the bicuspid aortic valve. Heart. 2000; 83: 81–85.[Free Full Text]
  39. Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol. 2002; 39: 1890–1900.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
Physiol. GenomicsHome page
S. Chakraborty, J. Cheek, B. Sakthivel, B. J. Aronow, and K. E. Yutzey
Shared gene expression profiles in developing heart valves and osteoblast progenitor cells
Physiol Genomics, September 17, 2008; 35(1): 75 - 85.
[Abstract] [Full Text] [PDF]


Home page
Infect. Immun.Home page
G. Tang, T. Kitten, C. L. Munro, G. C. Wellman, and K. P. Mintz
EmaA, a Potential Virulence Determinant of Aggregatibacter actinomycetemcomitans in Infective Endocarditis
Infect. Immun., June 1, 2008; 76(6): 2316 - 2324.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
R. B. Hinton Jr., C. M. Alfieri, S. A. Witt, B. J. Glascock, P. R. Khoury, D. W. Benson, and K. E. Yutzey
Mouse heart valve structure and function: echocardiographic and morphometric analyses from the fetus through the aged adult
Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2480 - H2488.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
P. Snider, R. B. Hinton, R. A. Moreno-Rodriguez, J. Wang, R. Rogers, A. Lindsley, F. Li, D. A. Ingram, D. Menick, L. Field, et al.
Periostin Is Required for Maturation and Extracellular Matrix Stabilization of Noncardiomyocyte Lineages of the Heart
Circ. Res., April 11, 2008; 102(7): 752 - 760.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
Y. Bosse, P. Mathieu, and P. Pibarot
Genomics: The Next Step to Elucidate the Etiology of Calcific Aortic Valve Stenosis
J. Am. Coll. Cardiol., April 8, 2008; 51(14): 1327 - 1336.
[Abstract] [Full Text] [PDF]


Home page
Br Med BullHome page
P. De Mozzi, U. G. Longo, G. Galanti, and N. Maffulli
Bicuspid aortic valve: a literature review and its impact on sport activity
Br. Med. Bull., March 1, 2008; 85(1): 63 - 85.
[Abstract] [Full Text] [PDF]


Home page
Toxicol PatholHome page
K. B. Donnelly
Cardiac Valvular Pathology: Comparative Pathology and Animal Models of Acquired Cardiac Valvular Diseases
Toxicol Pathol, February 1, 2008; 36(2): 204 - 217.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Pathol.Home page
A. C. Liu, V. R. Joag, and A. I. Gotlieb
The Emerging Role of Valve Interstitial Cell Phenotypes in Regulating Heart Valve Pathobiology
Am. J. Pathol., November 1, 2007; 171(5): 1407 - 1418.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
98/11/1431    most recent
01.RES.0000224114.65109.4ev1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hinton, R. B.
Right arrow Articles by Yutzey, K. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hinton, R. B., Jr
Right arrow Articles by Yutzey, K. E.
Related Collections
Right arrow Valvular heart disease
Right arrow Pediatric and congenital heart disease, including cardiovascular surgery
Right arrow Cardiac development